Zanzalintinib

Small molecule

Also known as XL092

Filedunder review

Evidence outlook · regulatory review

Colorectal Cancer: application under FDA review, decision date 2026-12-03

FDA accepts zanzalintinib NDA (2026-02-02). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: STELLAR-303 (NCT05425940) · Phase 3 · met primary endpoint · grade pending

Also in development:Non-Small Cell Lung Cancer · Phase 2Clear Cell Renal Cell Carcinoma · Phase 2Renal Cell Carcinoma · Phase 3

Source for the program status

Company guidance: topline data expected Second Half of 2026 (NCT05678673; Exelixis, 5 Aug 2026). “Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Colorectal Cancer
Renal Cell Carcinoma
NCT07227402 · Merck Sharp & Dohme LLC
2025-11-26 – 2033-03-21 · Renal Cell Carcinoma
What this study did
NCT07489495 · Merck Sharp & Dohme LLC
2026-04-09 – 2030-11-27 · Carcinoma, Renal Cell
What this study did
NCT07620574 · Exelixis
2026-07-30 – 2030-05-31 · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT06943755 · Exelixis
2025-07-21 – 2029-06-30 · Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
What this study did
NCT06082167 · Exelixis
2024-06-07 – 2029-03 · Head and Neck Squamous Cell Carcinoma
What this study did
Phase 2 (27)
Clear Cell Renal Cell Carcinoma
NCT07043608 · Kelly Fitzgerald, MD
2026-06-10 – 2030-04-30 · Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
What this study did
NCT07691476 · Yonsei University
2026-10-01 – 2029-02-01 · Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma
What this study did
NCT07578025 · City of Hope Medical Center
2026-11-28 – 2028-06-24 · Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
What this study did
Non-Small Cell Lung Cancer
NCT07845786 · Exelixis
2026-12-15 – 2030-06-15 · Squamous Non-Small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT06926634 · Washington University School of Medicine
2025-12-09 – 2034-12-31 · High Grade Neuroendocrine Neoplasms
What this study did
NCT06571734 · Northwestern University
2024-09-19 – 2033-07-01 · Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Bone Sarcoma, Translocation-associated Soft Tissue Sarcoma, Synovial Sarcomas, Osteosarcoma Metastatic, Ewing Sarcoma, Ewing Sarcoma Metastatic, Sarcoma Metastatic, Sarcoma of Bone
What this study did
NCT07470489 · M.D. Anderson Cancer Center
2026-10-29 – 2032-09-01 · Anaplastic Thyroid Cancer
What this study did
NCT07682675 · UNICANCER
2026-10 – 2032-04 · Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease
What this study did
NCT07714551 · Dana-Farber Cancer Institute
2027-01-09 – 2032-01-01 · Pheochromocytoma, Paraganglioma
What this study did
NCT07193550 · M.D. Anderson Cancer Center
2025-12-05 – 2031-10-31 · Bone Sarcomas
What this study did
NCT07623460 · Stuthi Perimbeti
2026-11 – 2031-09 · mCRPC (Metastatic Castration-resistant Prostate Cancer)
What this study did
NCT07283731 · M.D. Anderson Cancer Center
2026-04-14 – 2030-11-01 · Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue Sarcoma
What this study did
NCT06959511 · M.D. Anderson Cancer Center
2025-07-22 – 2030-10-01 · Neoadjuvant Treatment, Thyroid Cancer
What this study did
NCT06959641 · Jochen Lorch
2025-06-06 – 2030-09-11 · Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma, Locally Advanced Thyroid Gland Papillary Carcinoma, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Poorly Differentiated Thyroid Gland Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Poorly Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Oncocytic Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Thyroid Gland Follicular Carcinoma AJCC v8, Stage III Thyroid Gland Papillary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Thyroid Gland Follicular Carcinoma AJCC v8, Stage IV Thyroid Gland Papillary Carcinoma AJCC v8
What this study did
NCT07527169 · M.D. Anderson Cancer Center
2026-10-01 – 2030-07-01 · Metastatic Olfactory Neuroblastoma
What this study did
NCT07608718 · Pedro Barata, MD, MSc
2026-10 – 2030-05 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT07428616 · Exelixis
2026-05-21 – 2029-09-30 · Meningioma
What this study did
NCT07218666 · Deepak Kilari
2026-08-19 – 2029-07 · Aggressive Variant Prostate Carcinoma
What this study did
NCT07185945 · Guru Sonpavde
2026-10 – 2029-06 · Advanced Urothelial Carcinoma
What this study did
NCT07677579 · Northwell Health
2026-08-30 – 2028-12-30 · Colon Cancer Metastatic
What this study did
NCT06568562 · University of Utah
2024-12-09 – 2028-12 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT07226063 · Amit Mahipal
2026-05 – 2028-08 · Hepatocellular Carcinoma, Liver Cancer
What this study did
NCT07484139 · UNC Lineberger Comprehensive Cancer Center
2026-09-22 – 2028-05 · Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer
What this study did
NCT07511504 · OHSU Knight Cancer Institute
2026-04-02 – 2027-08-01 · Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
What this study did
NCT06698250 · Anwaar Saeed
2024-12-18 – 2027-04-30 · Hepatocellular Carcinoma
What this study did
Phase 1/2 (5)
Non-Small Cell Lung Cancer
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
Renal Cell Carcinoma
Other / comorbidity
NCT06937866 · Indiana University
2025-11-12 – 2031-09 · Germ Cell Tumor
What this study did
NCT07042919 · Devalingam Mahalingam
2026-03-30 – 2031-03-04 · Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
NCT07878689 · University of Texas Southwestern Medical Center
2026-12-01 – 2029-12-01 · Hepatocellular Carcinoma (HCC)
What this study did
Phase 1 (11)
Clear Cell Renal Cell Carcinoma
NCT06191796 · Exelixis
2024-01-25 – 2025-05-12 · Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
What this study did
Renal Cell Carcinoma
Other / comorbidity
NCT06957431 · Washington University School of Medicine
2025-10-22 – 2036-04-30 · Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma
What this study did
NCT06795009 · Washington University School of Medicine
2025-10-17 – 2035-04-30 · Uterine Cancer, Endometrial Cancer
What this study did
NCT06968988 · Washington University School of Medicine
2026-01-05 – 2034-01-31 · Metastatic Soft-tissue Sarcoma
What this study did
NCT06902376 · UNC Lineberger Comprehensive Cancer Center
2025-06-03 – 2028-08-31 · Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
What this study did
NCT07773454 · Exelixis
2026-09-30 – 2028-07-31 · Cancer, Pediatric Cancer
What this study did
NCT06952010 · Exelixis
2025-05-01 – 2027-11-30 · Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
What this study did
NCT06912087 · University of Chicago
2025-09-29 – 2027-06-05 · Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
What this study did
NCT06962332 · Exelixis
2025-05-13 – 2026-04 · Hepatic Impairment, Moderate Hepatic Impairment
What this study did

Competitive landscape

This drug's own stage for Clear Cell Renal Cell Carcinoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zanzalintinib: this drugPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
CasdatifanPhase 3Small moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
DarlifarnibPhase 1Small moleculeFarnesyltransferasenot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
XmAb819Phase 1Multispecific antibodyENPP3 x CD3not yet gradedNo reviewed efficacy summary in this indication
CTX131DiscontinuedCell therapyCD70not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(44 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zanzalintinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Metastatic Castration-resistant Prostate CancerRecruiting
Est. primary completion 2026-12 · NCT06568562 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-15 · NCT05678673 · CT.gov ↗

Company guidance: topline data expected Second Half of 2026 (Exelixis, 5 Aug 2026). “Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026.” Source ↗

What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06698250 · CT.gov ↗
What to watch
2027 (5)
January 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT05176483 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive TumorRecruiting
Est. primary completion 2027-05-31 · NCT06952010 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-06-05 · NCT06912087 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8 …Not yet recruiting
Est. primary completion 2027-08-01 · NCT07511504 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06863311 · CT.gov ↗
What to watch
2028 (19)
February 2028 (2)
Phase 2Hepatocellular Carcinoma, Liver CancerNot yet recruiting
Est. primary completion 2028-02 · NCT07226063 · CT.gov ↗
What to watch
Phase 2MeningiomaRecruiting
Est. primary completion 2028-02-29 · NCT07428616 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Neoadjuvant Treatment, Thyroid CancerRecruiting
Est. primary completion 2028-03-01 · NCT06959511 · CT.gov ↗
What to watch
Phase 1Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related TumorsRecruiting
Est. primary completion 2028-03-31 · NCT06902376 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Oral Cavity Squamous Cell Carcinoma, Head and Neck CancerRecruiting
Est. primary completion 2028-05 · NCT07484139 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2028-06-06 · NCT06794229 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-15 · NCT07845786 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-06-24 · NCT07578025 · CT.gov ↗
What to watch
July 2028 (4)
Phase 2Aggressive Variant Prostate CarcinomaRecruiting
Est. primary completion 2028-07 · NCT07218666 · CT.gov ↗
What to watch
Phase 2Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Bone Sarcoma, Translocation-associated Soft Tissue Sarcoma, Synovial Sarcomas …Recruiting
Est. primary completion 2028-07-01 · NCT06571734 · CT.gov ↗
What to watch
Phase 2Metastatic Olfactory NeuroblastomaRecruiting
Est. primary completion 2028-07-01 · NCT07527169 · CT.gov ↗
What to watch
Phase 1Cancer, Pediatric CancerNot yet recruiting
Est. primary completion 2028-07-31 · NCT07773454 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2/3Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-08 · NCT06082167 · CT.gov ↗
What to watch
Phase 2Colon Cancer MetastaticNot yet recruiting
Est. primary completion 2028-08-30 · NCT07677579 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2mCRPC (Metastatic Castration-resistant Prostate Cancer)Not yet recruiting
Est. primary completion 2028-09 · NCT07623460 · CT.gov ↗
What to watch
Phase 2Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma …Recruiting
Est. primary completion 2028-09-11 · NCT06959641 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Clear Cell Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07691476 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue SarcomaRecruiting
Est. primary completion 2028-11-01 · NCT07283731 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2028-12-01 · NCT07878689 · CT.gov ↗
What to watch
2029 (7)
March 2029 (1)
Phase 1/2Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8Recruiting
Est. primary completion 2029-03-04 · NCT07042919 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic DiseaseNot yet recruiting
Est. primary completion 2029-04 · NCT07682675 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2029-04-30 · NCT07043608 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Metastatic Castration-resistant Prostate CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07608718 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2/3Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)Recruiting
Est. primary completion 2029-06-30 · NCT06943755 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Bone SarcomasRecruiting
Est. primary completion 2029-10-31 · NCT07193550 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1Uterine Cancer, Endometrial CancerRecruiting
Est. primary completion 2029-11-30 · NCT06795009 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 1/2Germ Cell TumorRecruiting
Est. primary completion 2030-03 · NCT06937866 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2030-04-05 · NCT07750158 · CT.gov ↗
What to watch
May 2030 (1)
Phase 3Colorectal CancerEnrolling by invitation
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Anaplastic Thyroid CancerRecruiting
Est. primary completion 2030-09-01 · NCT07470489 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Renal Cell CarcinomaRecruiting
Est. primary completion 2030-11-27 · NCT07489495 · CT.gov ↗
What to watch
2031 (3)
January 2031 (1)
Phase 2Pheochromocytoma, ParagangliomaNot yet recruiting
Est. primary completion 2031-01-01 · NCT07714551 · CT.gov ↗
What to watch
May 2031 (1)
Phase 1Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced LiposarcomaRecruiting
Est. primary completion 2031-05-31 · NCT06957431 · CT.gov ↗
What to watch
October 2031 (1)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2031-10-26 · NCT07049926 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 3Renal Cell CarcinomaRecruiting
Est. primary completion 2032-02-27 · NCT07227402 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 2High Grade Neuroendocrine NeoplasmsRecruiting
Est. primary completion 2034-12-31 · NCT06926634 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

3 December 2026FDA action datePDUFA target action date December 3, 2026
US, FDA · Source ↗

Recent

22 June 2026Topline resultSTELLAR-303 NLM overall survival final analysis
2 February 2026Filing acceptedFDA accepts zanzalintinib NDA
US, FDA · Exelixis · Source ↗
23 June 2025Topline resultSTELLAR-303 Phase 3 topline results
Exelixis · Source ↗